A significant shareholder in Core Scientific, Two Seas Capital, which holds a 6.3% stake, has publicly declared its intention to vote against the proposed all-stock acquisition by CoreWeave. In a statement released on Thursday, Two Seas Capital outlined its plans to mobilize other shareholders to reject the deal unless substantial revisions are made. The primary concern stems from the all-stock nature of the transaction, which Two Seas Capital believes disproportionately favors CoreWeave and fails to acknowledge Core Scientific's strategic position in the high-performance computing infrastructure sector.
According to Sina Toussi, founder of Two Seas Capital, 'the proposed sale significantly undervalues the company and exposes its shareholders to considerable economic risk.' Core Scientific's stock price has experienced a modest increase, currently trading at $14.24, substantially lower than the estimated $20 it would have been worth at the time of the proposed acquisition. Two Seas Capital has been a supporter of Core Scientific since 2022, participating in its post-bankruptcy restructuring and financing rounds, and still believes in the company's long-term value, preferring it to remain independent if a more favorable offer does not emerge.
Despite also holding a stake in CoreWeave and supporting the idea of a merger, Two Seas Capital has expressed disappointment with the current deal, citing the 30% decline in Core Scientific's stock price following the announcement as evidence of investor concern. The firm has urged the board to explore alternative bids, including from CoreWeave, but only at terms that accurately reflect the full strategic value of Core Scientific's assets and growth prospects. Further analysis and engagement with shareholders are expected in the coming weeks. Investment bank KBW analysts had predicted that Core Scientific shareholders might resist the terms of the deal due to the unchanged asset base since CoreWeave's initial failed bid and the lack of a cash component.